

AD _____

Award Number: DAMD17-03-1-0738

TITLE: Predictors of Lymphedema Following Breast Cancer

PRINCIPAL INVESTIGATOR: Karen K. Swenson

CONTRACTING ORGANIZATION: Park Nicollet Institute
St. Louis Park, MN 55416

REPORT DATE: September 2005

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20060503160

REPORT DOCUMENTATION PAGE				<i>Form Approved</i> OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) 01-09-2005		2. REPORT TYPE Annual Summary		3. DATES COVERED (From - To) 1 Sep 2003 - 31 Aug 2005	
4. TITLE AND SUBTITLE Predictors of Lymphedema Following Breast Cancer				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER DAMD17-03-1-0738	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Karen K. Swenson E-mail: swensk@parknicollet.com				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Park Nicollet Institute St. Louis Park, MN 55416				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Surgery for breast cancer includes removal of the breast tumor along with the axillary lymph nodes. The status of these nodes helps clinicians determine prognosis and guides treatment decisions. Unfortunately, a relatively common side effect following axillary lymph node dissection is upper-extremity lymphedema. The purpose of this study is to identify risk factors for lymphedema among women who have had axillary surgery for breast cancer. Specific aims include identifying risk factors for lymphedema and comparing quality of life (QOL) ratings for women who have and do not have lymphedema. A case-control study will be conducted with enrollment of 200 participants. Cases will be identified in the physical therapy or cancer centers. Using the oncology registry, controls will include patients who have had breast cancer surgery and have not developed lymphedema. The severity of lymphedema and interference with daily life will be assessed with the Measure of Arm Symptom Survey (MASS), a patient-completed survey, and QOL will be collected with the SF-36. Treatment risk factors including previous surgery, radiotherapy and chemotherapy will be obtained from oncology registry data. This study will determine which factors play a role in lymphedema development.					
15. SUBJECT TERMS No subject terms provided.					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 10	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

Cover.....	
SF 298.....	
Table of Contents.....	
Introduction.....	1
Body.....	1
Key Research Accomplishments.....	3
Reportable Outcomes.....	4
Conclusions.....	4
References.....	6

I. Introduction

Lymphedema is a common problem for patients diagnosed with breast cancer, with an estimated 6 – 35% developing it sometime after breast cancer treatment.¹⁻¹⁵ In 2005, it is estimated that 211,240 women will be diagnosed with breast cancer, and 88% of these women will survive at least 5 years.¹⁶ The reported incidence of lymphedema varies with the length of follow-up, the measurement techniques, and other patient and treatment-related factors.⁵ It can range from mild to severe, and can be a chronic condition that affects patients' quality of life for years after cancer surgery. Patients are interested in learning how to prevent lymphedema because it is one of the more feared side effects following completion of treatment.

A less invasive procedure, sentinel lymph node dissection (SLND), has shown a reduction in reported lymphedema and other arm symptoms.^{9, 22 - 25} In a study conducted at Park Nicollet Institute, 4.7% of SLND patients reported arm swelling at six months after surgery versus 19.5% of ALND patients ($p < .001$).²² However, patients are not eligible for SLND if they have clinically positive nodes, a pathologically positive sentinel node, or if the surgeon is unable to locate the sentinel lymph node.

Several treatment-related factors have been associated with lymphedema including the extent of axillary dissection, axillary radiation therapy after surgery, type of surgery, and the presence of infection in the ipsilateral arm.^{2-6, 12, 26-31} Several patient-related factors have also been evaluated for their association with lymphedema in breast cancer patients including body mass index, airline travel, hypertension, diabetes, smoking and age at breast cancer diagnosis, and findings have been inconsistent.^{1, 3-5, 12, 14, 15, 29, 32}

Previous studies have several limitations. Most of the studies have a small sample size without a comparison group, making it difficult to determine which factors are significantly associated with lymphedema. The surgery and treatments for breast cancer have changed in recent years, with a higher proportion of patients now having lumpectomies, sentinel lymph node dissections, and adjuvant treatments. Women are advised to avoid lifting weights, constrictive pressure, and activities that could lead to arm injury or infection, but most of this advice is based on very limited data. Therefore, there is a need for additional studies to identify factors that contribute to the development of lymphedema in breast cancer patients.

II. Body

Specific aims. The primary specific aim of this study is to identify risk factors for lymphedema among women who have had axillary surgery for breast cancer. Secondary aims are: 1) to evaluate which factors predict moderate/severe lymphedema in patients who have lymphedema, 2) to describe patients' rating of the interference with daily life caused by lymphedema, 3) to compare the reported quality of life using the SF-36 (Short Form-36) for patients with and without lymphedema, 4) to compare arm circumference measurements to patient-reported lymphedema, and 5) to identify the cause(s) to which patients attribute their lymphedema.

Study design. This study uses a matched case-control design, which permits identification of risk factors that are present more often in lymphedema cases than in controls who have had breast cancer surgery but have not developed lymphedema. Lymphedema cases will be identified at the time they present to the physical therapy or cancer centers at four participating institutions – Park Nicollet Health Services (Methodist Hospital), Fairview-University Medical Center, Fairview

Southdale Medical Center, and the Humphrey Cancer Institute. The protocol and consent forms for the study were reviewed and approved by the participating institutional review boards and the Department of Defense HSRRB.

Research subjects. Eligibility criteria for cases include: a clinical diagnosis of lymphedema, unilateral axillary surgery for invasive breast cancer, no known metastatic disease present, and ability and willingness to give consent. Control participants will be identified using the oncology registry. Eligibility criteria for controls include: no upper extremity lymphedema, unilateral axillary surgery for invasive breast cancer, no known metastatic disease, and ability and willingness to give consent. Controls will be matched to cases on date of axillary surgery (within 3 months) and type of axillary dissection (sentinel versus axillary lymph node dissection). Controls will not be matched on age or other factors because matching on a variable precludes the possibility of assessing its role as a potential risk factor. Using previous literature to estimate effect size, sample size for this study is set at 100 cases and 100 controls.

Questionnaires. The Measure of Arm Symptom Survey (MASS-Version 3) will be administered to cases and controls as a subjective measure of lymphedema. Breast cancer patients with lymphedema (i.e., cases) are asked to complete a revised questionnaire (MASS – Version 3 lymphedema) with questions referencing the date of the onset of arm swelling. Potential lymphedema risk factors are assessed in the MASS including diabetes, hypertension, smoking, past shoulder injury, flexibility exercises, strength training exercises, medical procedures, arm/hand injury, airline travel, body mass index (BMI) and occupation. The questionnaires address the severity of symptoms by having patients rate them on a 5-point Likert-type scale from no swelling to very severe swelling. The degree of interference with life activities will be assessed using a similar 5-point scale of “not at all” to “very much”. The MOS 36-Item Short-Form Health Survey (SF-36) will be administered to cases and controls to assess general health-related quality of life. This questionnaire uses two summary component scales (physical and mental), and higher scores reflect greater quality of life. To assess test-retest reliability, a second MASS questionnaire will be mailed to the first 20 cases in the study within two weeks after the initial questionnaires are completed. After reliability information is collected on 20 cases, the questionnaires will be administered on a one-time basis.

Setting. Patients are being recruited from four clinics in Minneapolis, Minnesota. Park Nicollet Health Services (PNHS) is a large multi-specialty clinic with approximately 370 breast cancer cases diagnosed annually. Fairview-University Medical Center (F-UMC) is a National Cancer Institute-designated Comprehensive Cancer Center with approximately 150 breast cancer cases diagnosed annually. Fairview Southdale Medical Center (FSMC) is affiliated with a regional hospital with approximately 300 breast cancer cases diagnosed annually. The Humphrey Cancer Institute (HCI) is affiliated with North Memorial Medical Center, a regional hospital with approximately 320 breast cancer cases diagnosed annually. Adequate numbers of control patients are available because of the large number of breast cancer patients diagnosed annually.

Data analysis. Univariate analysis will be conducted to describe the characteristics of cases and controls. Chi-square tests will be used to compare cases and controls on potential risk factors for lymphedema. Conditional logistic regression analysis will be used to model the association of potential risk factors with the presence of lymphedema.

III. Key Research Accomplishments

- Preparations to begin the study
 - Determined staff and roles on the study
 - Reviewed and revised MASS instrument with input from the lymphedema education group
 - Presented study and consent forms to 3 local IRBs (Fairview IRB is used for both Fairview University and Fairview Southdale sites) and received approval to begin enrollment
 - Received approval from the USAMRMC HSRRB to enroll research subjects
 - Developed database and data dictionary for the study
- Accrual and data collection
 - Between 12/03 and 8/05 a total of 24 participants have been enrolled (13 participants from Methodist Hospital, 4 participants from the Humphrey Cancer Institute, 7 participants from Fairview-University).
 - Matched controls have been identified for the 24 cases and surveys have been sent to controls.
 - Arm measurement have been taken and recorded on all cases
 - Reliability MASS questionnaires were mailed to enrolled cases within two weeks of enrollment.
 - Treatment data has been collected from the medical records on all participants.
 - IRB annual approval was granted from 3 local IRBs (Fairview IRB is used for both Fairview University and Fairview Southdale sites) and the USAMRMC HSRRB to continue enrollment of research subjects at the four institutions.
 - Entered demographic and treatment data for the cases and controls currently accrued and summarized data (see Table 1).

Table 1. Demographic and treatment data for cases and controls enrolled to date

Factors	Cases (n = 24)	Controls (n = 16)
Mean age	57.1	61.1
Mean # of nodes removed	13.4	14.2
Mean # of nodes positive	2.6	1.4
% receiving mastectomy	79.2%	50.0%
% receiving reconstructive surgery	20.8%	25.0%
% receiving radiation therapy	62.5%	81.3%
% receiving chemotherapy	82.6%	62.5%
% receiving hormone therapy	56.5%	87.5%

- Amendments have been reviewed and approved by the three IRBs and the HSRRB at the DoD for the study:
 - Amendment #1 (4/24/03) made administrative changes in the study which clarified eligibility criteria, changed study design to a matched case control design with conditional logistic regression, modified the MASS to version 3.
 - Amendment #2 (10/14/03) revised the subject letter, and made administrative changes in the protocol.
 - Amendment #3 (2/17/04) changed the eligibility criteria from 10% to 5% difference between arms in patient's total arm girth.
 - Amendment #4 (7/9/04) changed the eligibility criteria from 5% to "a clinical diagnosis of lymphedema" and changed the enrollment procedures for controls to absence of a clinical diagnosis of lymphedema.
 - Amendment # 5 (5/6/05) changed recruitment goal to 100 cases and 100 controls, includes cases identified in the cancer centers as well as the lymphedema centers, and includes both incident and prevalent lymphedema cases.

IV. Reportable Outcomes

- Research training of the candidate
 - Karen Swenson, RN, MS, AOCN completed her coursework requirements for her doctoral program at the University of Minnesota (41 credit hours). She is currently a doctoral candidate following the completion of the first and second preliminary papers and the oral prelim examination on 9/10/04. The expected completion date for her doctorate is 01/30/06.
- Enrollment of research participants
 - Enrollment of 24 lymphedema cases and 16 controls
 - Completion of SF-36 and MASS questionnaires, with a second set of MASS reliability questionnaires sent to 15 research participants (11 returned).
- Meetings and training with participating sites
 - Quarterly meetings have been conducted at the participating sites to discuss training, enrollment issues, and possible changes to improve site enrollment.
 - Several changes have been made in the protocol (Amendments 1 – 5) to improve the enrollment process at the sites, including making changes in the eligibility criteria, revising and further defining the enrollment process, and ongoing training at all of the sites.
- A poster presentation P20-15 entitled "Predictors of lymphedema following breast cancer surgery" was presented at the Era of Hope Department of Defense Breast Cancer Research Program Meeting, June 8 – 11, 2005.

V. Conclusions

This research project has provided the candidate with a valuable learning experience in designing and conducting a case-control study. The candidate has successfully completed coursework for the nursing doctoral program and has advanced to candidacy in the program. This grant has provided the candidate with experience in conducting a multi-center breast cancer study, managing the regulatory process, revising and validating the MASS questionnaire, recruiting and enrolling research participants, and collecting questionnaire data from participants.

Enrollment has been slower than projected in the Statement of Work. With the advent of sentinel lymph node dissection in 1999, the lymphedema incidence after breast cancer surgery has decreased considerably. To increase enrollment, both incident and prevalent cases are now eligible. Another modification includes decreasing the study sample size from 200 to 100 matched pairs. The power and minimal effect size with 100 matched pairs have been recalculated and are listed below in Table 2. The revision in sample size decreases the power to detect the estimated effect size of some of the variables, but remains at an acceptable level for most of the variables. A request has been submitted for an extension so the sample size can be achieved.

The overall goal of this study is to identify modifiable risk factors for lymphedema in patients who have had breast cancer surgery. This is an important area of study because currently there is little research guiding lymphedema prevention recommendations. If modifiable risk factors are identified in this study, they will lead to further research by the investigators on the effectiveness of education and other strategies to prevent lymphedema after breast cancer treatment.

Table 2. Sample size calculations are based on 100 matched pairs (200 participants). Calculations were made to determine the power to detect the estimated effect size, and the minimal effect size (OR) that the study could detect. Six variables are added, and the minimal effect size is calculated for each variable.

Variable	Estimated Odds Ratio	Power (1- β)	Minimal Detectable Effect (OR)
RT (yes/no) ²⁹	2.85	.91	2.23
Axillary RT (yes/no) ²⁹	6.31	.99	2.30
Infection (yes/no) ²⁹	16.78	.99	2.96
Tumor size (T2,T3,T4 versus T1) ³³	1.78	<.5	2.23
Nodal status (N1,N2,N3 versus N0) ³³	1.82	.55	2.23
Dissection (ALN vs. SLN) ²³	6.74	.99	2.30
Weight (BMI>27.2 vs. \leq 27.2) ²⁹	1.49	<.5	2.23
Tumor location (UO vs. other) ²³	2.19	.76	2.23
Age (>55 vs. \leq 55) ⁶	1.89	.60	2.23
Smoking			2.30
Hypertension			2.30
Diabetes			2.96
Arm/shoulder injury			2.96
Stretching			2.30
Strength training			2.96

References

1. Edwards TL. Prevalence and aetiology of lymphedema after breast cancer treatment in southern Tasmania. *Aust N Z Surg* 2000;70(6):412-418.
2. Hoe AL, Iven D, Royle GT, Taylor I. Incidence of arm swelling following axillary clearance for breast cancer. *Br J Surg* 1992;79(3):261-262.
3. Hojris I, Andersen J, Overgaard M, Overgaard J. Late treatment-related morbidity in breast cancer patients randomized to postmastectomy radiotherapy and systemic treatment versus systemic treatment alone. *Acta Oncol* 2000;39(3):355-372.
4. Ivens D, Hoe AL, Podd TJ, Hamilton CR, Taylor I, Royle GT. Assessment of morbidity form complete axillary dissection. *Br J Cancer* 1992;66(1):136-138.
5. Kakuda JT, Stuntz M, Trivedi V, Klein SR, Vargas HI. Objective assessment of axillary morbidity in breast cancer treatment. *Am Surg* 1999;65(10):995-998.
6. Kiel KD, Rademacker AW. Early-stage breast cancer: Arm edema after wide excision and breast irradiation. *Radiology* 1996;198:279-283.
7. Petrek JA, Heelan MC. Incidence of breast carcinoma-related lymphedema. *Cancer* 1998;83(12):2776-2781.
8. Paci E, Cariddi A, Barchielli A, Bianchi S, Cardona G, Distanti V, Giorgi D, Pacini P, Zappa M, Del Turco MR. Long-term sequelae of breast cancer surgery. *Tumori* 1996;82(4):321-324.
9. Schrenk P, Rieger R, Shamiyeh A, Wayand W. Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. *Cancer* 2000;88:608-614.
10. Stotter A, Chandler T. Breast cancer: outcome audit of axillary management in 1991. *Eur J Surg Oncol* 1999; 25(3):261-264.
11. Tasmuth T, vonSmitten K, Kalso E. Pain and other symptoms during the first year after radical and conservative surgery for breast cancer. *Br J Cancer* 1996;74(12):2024-31.
12. Tengrup I, Tennvall-Nittby L, Christiansson I, Laurin M. Arm morbidity after breast-conserving therapy for breast cancer. *Acta Oncol* 2000;39(3):393-397.
13. Suneson BL, Lindholm C, Hamrin E. Clinical incidence of lymphoedema in breast cancer patients in Jonkoping County, Sweden. *Eur J Cancer Care (Engl)* 1996;5(1):7-12.
14. Warmuth MA, Bowen G, Prosnitz LR, Chu L, Broadwater G, Peterson B, Leight G, Winer EP. Complications of axillary lymph node dissection for carcinoma of the breast: A report based on a patient survey. *Cancer* 1998;83(7):1362-1368.
15. Werner RS, McCormick B, Petrek J, Cox L, Cirrincione C, Gray JR, Yahalom J. Arm edema in conservatively managed breast cancer: Obesity is a major predictive factor. *Radiology* 1991;180:177-184.
16. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. *CA: A Cancer Journal for Clinicians* 2005;55, 10-30.
17. Carter BJ. Women's experiences of lymphedema. *Oncol Nurs Forum* 1997;24(5):875-882.
18. Maunsell E, Brisson J, Deschenes L. Arm problems and psychological distress after surgery for breast cancer. *Can J Surg* 1993;36(4):315-379.
19. Passik SD, McDonald MV. Psychosocial aspects of upper extremity lymphedema in women treated for breast carcinoma. *Cancer* 1998;83(12):2817-2820.
20. Tobin MB, Lacey HJ, Meyer L, Mortimer PS. The psychosocial morbidity of breast cancer-related arm swelling. Psychological morbidity of lymphoedema. *Cancer* 1993;72(11):3248-3252.

21. Velanovich V, Szymanski W. Quality of life of breast cancer patients with lymphedema. *Am J Surg* 1999;177(3):184-187.
22. Swenson KK, Nissen MJ, Ceronsky L, Swenson L, Lee M, Tuttle TM. Comparison of side effects between sentinel lymph node and axillary lymph node dissection for breast cancer. *Ann Surg Oncol* 2002;9(8):745-753.
23. Sener SF, Winchester DJ, Martz CH, Feldman JL, Cavanaugh JA, Winchester DP, Weigel B, Bonnefoi K, Kirby K, Morehead C. Lymphedema after sentinel lymphadenectomy for breast carcinoma. *Cancer* 2001;92:748-752.
24. Burak WE, Hollenbeck ST, Zervos EE, Hock KL, Kemp LC, Young DC. Sentinel lymph node biopsy results in less postoperative morbidity compared with axillary lymph node dissection for breast cancer. *Am J Surg* 2002;183:23-27.
25. Baron RH, Fey JV, Raboy S, Thaler HT, Borgen PI, Temple LKF, Van Zee KJ. Eighteen sensations after breast cancer surgery: A comparison of sentinel lymph node biopsy and axillary lymph node dissection. *Onc Nurs Forum* 2002;29(4):651-659.
26. Keramopoulos A, Tsionou C, Minaretzis D, Michalas S, Aravantinos D. Arm morbidity following treatment of breast cancer with total axillary dissection: a multivariate approach. *Oncology* 1993;50:445-449.
27. Liljegren G, Holmberg L, et al. Arm morbidity after sector resection and axillary dissection with or without postoperative radiotherapy in breast cancer stage I. Results from a randomised trial. *Eur J Cancer* 1997;33(2):193-199.
28. Kissin MW, Rovere GQD, Easton D, Westbury G. Risk of lymphoedema following the treatment of breast cancer. *Br J Surg* 1986;73:580-584.
29. Segerstrom K, Bjerle P, Graffman S, Nystrom A. Factors that influence the incidence of brachial oedema after treatment of breast cancer. *Scand J Plast Reconstr Surg Hand Surg* 1992;26(2):223-227.
30. Senofsky GM, Moffat FL Jr, Davis K, Masri MM, Clark KC, Robinson DS, Sabates B, Ketcham AS. Total axillary lymphadenectomy in the management of breast cancer. *Arch Surg* 1991;126(11):1336-1341.
31. Gerber L, Lampert M, Wood C, Duncan M, D'Angelo T, Schain W, McDonald H, Danforth D, Findlay P, Glatstein E. et al. Comparison of pain, motion, and edema after modified radical mastectomy vs. local excision with axillary dissection and radiation. *Breast Cancer Res Treat* 1992;21(2):139-145.
32. Casley-Smith J, Casley-Smith J. Lymphedema initiated by aircraft flights. *Aviat Space Environ Med* 1996;67:52-56.
33. Kocak Z, Overgaard J. Risk factors of arm lymphedema in breast cancer patients. *Acta Oncologica* 2000;39(3):389-392.